StockData
ENDRA Life Sciences Inc. logo

ENDRA Life Sciences Inc. (NDRA) stock

NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$4.04+0.12 (+2.93%)

Close on Nov 18, 2026Market cap $6.05MP/E –Yield –

ENDRA Life Sciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ENDRA Life Sciences's free cash flow for the twelve months ending Dec 31, 2025 was -$5.20M. For fiscal 2025 it was -$5.20M. The highest annual figure on record is -$3.31M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$5.20M–
FY2024Dec 31, 2024-$7.42M–
FY2023Dec 31, 2023-$9.58M–
FY2022Dec 31, 2022-$12.97M–
FY2021Dec 31, 2021-$11.17M–
FY2020Dec 31, 2020-$10.82M–
FY2019Dec 31, 2019-$8.63M–
FY2018Dec 31, 2018-$7.80M–
FY2017Dec 31, 2017-$3.31M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$1.61M–
Q3 FY2025Sep 30, 2025-$1.16M–
Q2 FY2025Jun 30, 2025-$1.11M–
Q1 FY2025Mar 31, 2025-$1.31M–
Q4 FY2024Dec 31, 2024-$1.52M–
Q3 FY2024Sep 30, 2024-$1.66M–
Q2 FY2024Jun 30, 2024-$2.07M–
Q1 FY2024Mar 31, 2024-$2.17M–
Q4 FY2023Dec 31, 2023-$2.18M–
Q3 FY2023Sep 30, 2023-$2.60M–
Q2 FY2023Jun 30, 2023-$2.27M–
Q1 FY2023Mar 31, 2023-$2.53M–
Q4 FY2022Dec 31, 2022-$3.13M–
Q3 FY2022Sep 30, 2022-$3.26M–
Q2 FY2022Jun 30, 2022-$3.39M–
Q1 FY2022Mar 31, 2022-$3.19M–
Q4 FY2021Dec 31, 2021-$2.65M–
Q3 FY2021Sep 30, 2021-$2.75M–
Q2 FY2021Jun 30, 2021-$2.80M–
Q1 FY2021Mar 31, 2021-$2.97M–
Q4 FY2020Dec 31, 2020-$2.14M–
Q3 FY2020Sep 30, 2020-$2.12M–
Q2 FY2020Jun 30, 2020-$3.45M–
Q1 FY2020Mar 31, 2020-$3.11M–
Q4 FY2019Dec 31, 2019-$1.95M–
Q3 FY2019Sep 30, 2019-$2.48M–
Q2 FY2019Jun 30, 2019-$1.66M–
Q1 FY2019Mar 31, 2019-$2.55M–
Q4 FY2018Dec 31, 2018-$1.90M–
Q3 FY2018Sep 30, 2018-$1.57M–
Q2 FY2018Jun 30, 2018-$1.88M–
Q1 FY2018Mar 31, 2018-$2.45M–
Q4 FY2017Dec 31, 2017-$1.38M–
Q3 FY2017Sep 30, 2017-$546.61K–

More ENDRA Life Sciences figures

See a number that looks wrong?